article thumbnail

MHRA authorises new COVID-19 vaccine

European Pharmaceutical Review

A new COVID-19 vaccine has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA). Bimervax is now the ninth vaccine to be authorised by the UK’s independent medicines regulator to treat the virus. This is an additional ingredient designed to trigger a stronger immune response.

article thumbnail

Key vaccine adjuvant biosynthesised

European Pharmaceutical Review

A paper, published in Nature Chemical Biology has reported the first ‘free-from ‘tree’ production of a key vaccine ingredient sourced from the soapbark tree. Bioengineering vaccine adjuvants The paper explained: “QS-21 is a potent vaccine adjuvant currently sourced by extraction from the Chilean soapbark tree.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Accelerating AMR vaccine development

European Pharmaceutical Review

In July 2022, the World Health Organization (WHO) released its inaugural report on the pipeline of vaccines currently in development to prevent infections caused by antimicrobial resistance (AMR) bacterial pathogens. WHO referred to 61 bacterial vaccine candidates in diverse stages of clinical development. 1 WHO’s analysis was stark.

article thumbnail

The imperative of fridge-free vaccines

European Pharmaceutical Review

Many of today’s vaccines are produced in ready-to-inject liquid formulations that must be kept cold to maintain stability. However, this greatly complicates both the worldwide distribution and stockpiling of vaccines and other drugs. A requisite cold chain has been designed and implemented to be uninterrupted from factory to patient.

article thumbnail

Meningitis vaccine comes to the forefront with impressive study results

Pharmaceutical Technology

A new vaccine developed by the Serum Institute of India to fight meningococcal disease could help eliminate meningitis across Africa. The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. for serogroup W to 20.5

article thumbnail

First COVID-19 impact report on global vaccine markets

European Pharmaceutical Review

The World Health Organization (WHO)’s Global Vaccine Market Report 2022 , the first report to examine the impact of COVID-19 on the global vaccine market, shows that inequitable distribution is not unique to COVID-19 vaccines, with poorer countries consistently fighting to access vaccines in demand by wealthier countries.

article thumbnail

Reconfiguring COVID and influenza vaccines for long-term effectiveness

pharmaphorum

Alexandre Le Vert, CEO and co-founder of Osivax, discusses the company’s breakthrough vaccine technology, oligoDOM, and how it’s driving the development of new influenza and SARS-CoV-2 vaccines that attack T-cells, providing a long-lasting effect. The technology.